Dr. John Hubbard is the President and CEO of Bioclinica. He is a leader in the Clinical Services and Biopharmaceutical R&D industries, with over three decades of experience including executive level positions at Pfizer, ICON, Parexel and Hoechst Marion Roussel Pharmaceuticals. Prior to joining Bioclinica, he was Senior Vice President and Worldwide Head of Development Operations for Pfizer, where he directed and oversaw clinical trial operations and management of more than 450 clinical projects. Dr. Hubbard was also a founding member of the Board of Directors of TransCelerate Biopharma, Inc. Before joining Pfizer, Dr. Hubbard was Group President, Clinical Research Services at ICON Clinical Research, a top five global clinical research organization. He is also a Board Member of Agile Therapeutics, a Board Member of the Association of Clinical Research Organizations (ACRO), and an Advisory Board Member and Fundraising Vice-chair for the Children's Brain Tumor Foundation. Dr. Hubbard received a Bachelor of Science degree in Biopsychology from the University of Santa Clara and a Doctorate from the University of Tennessee, with a research focus on the genetic basis of hypertension and autonomic dysfunction. He was an NIH Postdoctoral Fellow in Cardiovascular and Clinical Pharmacology at the University of Texas Health Sciences Center. Dr. Hubbard is an active member of the Society of Clinical Pharmacology and Therapeutics, a Board Certified Diplomate in Applied Pharmacology and was elected as a Fellow of the American College of Clinical Pharmacology (ACCP). He has authored/co-authored three book chapters and 76 published articles and abstracts in the areas of biopsychology, cardiovascular and autonomic pharmacology, clinical pharmacology, and global drug development.

Drug development, Therapeutics, Project Management, Biopsychology, cardiovascular, clinical pharmacology and global drug development, Pharmaceutical research and development, Clinical trial, Clinical Research ,Pharmacovigilance